Updates On Phase1b/2 Trial Of The Indoleamine 2,3-Dioxygenase Pathway (Ido) Inhibitor Indoximod Plus Checkpoint Inhibitors For The Treatment Of Unresectable Stage 3 Or 4 Melanoma
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要